Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Male and female subjects with multiple myeloma or plasmacytoma
• Very good partial or complete remission (CR) after prior combination therapies.
• Expected survival \> 12 weeks
• Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
• Voluntary informed consent is given with willingness to continue follow up
Locations
Other Locations
China
Shenzhen Geno-immune Medical Institute
RECRUITING
Shenzhen
Russian Federation
The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health
RECRUITING
Vladivostok
Contact Information
Primary
Lung-Ji Chang, ph.D
c@szgimi.org
86-0755-86725195
Time Frame
Start Date: 2024-05-11
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 10
Treatments
Experimental: DCvac cells to treat MM
Related Therapeutic Areas
Sponsors
Leads: Shenzhen Geno-Immune Medical Institute
Collaborators: The No.2 Clinical Hospital of the Ministry of Health